Platelet bound complement split product (PC4d) is a marker of platelet activation and arterial vascular events in Systemic Lupus Erythematosus

被引:10
|
作者
Gartshteyn, Yevgeniya [1 ]
Mor, Adam [1 ]
Shimbo, Daichi [2 ]
Khalili, Leila [1 ]
Kapoor, Teja [1 ]
Geraldino-Pardilla, Laura [1 ]
Alexander, Roberta V. [3 ]
Conklin, John [3 ]
Dervieux, Thierry [4 ]
Askanase, Anca D. [1 ]
机构
[1] Columbia Univ, Med Ctr, Dept Med, Div Rheumatol, New York, NY USA
[2] Columbia Univ, Med Ctr, Ctr Behav Cardiovasc Hlth, Dept Med,Div Cardiol, New York, NY USA
[3] Exagen Diagnostics Inc, Vista, CA USA
[4] Prometheus Biosci, San Diego, CA USA
基金
美国国家卫生研究院;
关键词
Systemic lupus erythematosus; Cardiovascular disease; Thrombosis; Antiphospholipid syndrome; Complement split products; Platelet; Inflammation; Autoimmune disease; Biomarker; DISEASE-ACTIVITY; C4D; CLASSIFICATION; THROMBOSIS; CRITERIA; SIZE;
D O I
10.1016/j.clim.2021.108755
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Platelet-bound complement activation products (PC4d) are associated with thrombosis in Systemic Lupus Erythematosus (SLE). This study investigated the effect of PC4d on platelet function, as a mechanistic link to arterial thrombosis. In a cohort of 150 SLE patients, 13 events had occurred within five years of enrollment. Patients with arterial events had higher PC4d levels (13.6 [4.4-24.0] vs. 4.0 [2.5-8.3] net MFI), with PC4d 10 being the optimal cutoff for event detection. The association of arterial events with PC4d remained significant after adjusting for antiphospholipid status, smoking, and prednisone use (p = 0.045). PC4d levels correlated with lower platelet counts (r = -0.26, p = 0.002), larger platelet volumes (r = 0.22, p = 0.009) and increased platelet aggregation: the adenosine diphosphate (ADP) concentration to achieve 50% maximal aggregation (EC50) was lower in patients with PC4d 10 compared with PC4d < 10 (1.6 vs. 3.7, p = 0.038, respectively). These results suggest that PC4d may be a mechanistic marker for vascular disease in SLE.
引用
收藏
页数:7
相关论文
共 38 条
  • [31] Increased phosphate content in complement component C3, fibrinogen, vitronectin, and other plasmaproteins in systemic lupus erythematosus -: Covariation with platelet activation and possible association with thrombosis
    Ekdahl, KN
    Rönnblom, L
    Sturfelt, G
    Nilsson, B
    ARTHRITIS AND RHEUMATISM, 1997, 40 (12): : 2178 - 2186
  • [32] Cell bound complement activation products alone and in combination with low serum complement C3 or C4 have superior diagnostic performance in systemic lupus erythematosus
    Weinstein, Arthur
    Wallace, Daniel J.
    Putterman, Chaim
    Arriens, Cristina
    Askanase, Anca
    Kalunian, Kenneth C.
    Collins, Christopher E.
    Saxena, Amit
    Massarotti, Elena M.
    Alexander, Roberta Vezza
    Ibarra, Claudia
    Chatham, Winn
    Ramsey-Goldman, Rosalind
    Narain, Sonali
    Chandra, Tarun
    Ahearn, Joseph
    Manzi, Susan
    Dervieux, Thierry
    JOURNAL OF IMMUNOLOGY, 2019, 202 (01):
  • [33] Cell-bound complement activation products are superior to serum complement C3 and C4 levels to detect complement activation in systemic lupus erythematosus: comment on the article by Aringer et al Reply
    Aringer, Martin
    Costenbader, Karen H.
    Doerner, Thomas
    Johnson, Sindhu R.
    ARTHRITIS & RHEUMATOLOGY, 2020, 72 (05) : 860 - 861
  • [34] Complement C4d Split Products on Erythrocytes Are Associated with Composite Measure of Disease Activity in Systemic Lupus Erythematosus Subjects Receiving Methotrexate and Hydroxychloroquine
    Petri, Michelle
    Qu, Ying
    Conklin, John
    Brady, Kelley
    Apilado, Robert
    Dervieux, Thierry
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [35] Cell Bound Complement Activation Products Have Higher Sensitivity Than Serum C3 and C4 Levels in Systemic Lupus Erythematosus.
    Ramsey-Goldman, Rosalind
    Furie, Richard
    Putterman, Chaim
    Askanase, Anka
    Buyon, Jill P.
    Kalunian, Kenneth
    Chatham, W. Winn
    Massarotti, E.
    Kirou, Kyriakos A.
    Weinstein, A.
    Chitkara, Puja
    Manzi, Susan
    Ahearn, Joe
    Wolover, Leilani
    Conklin, John
    O'Malley, Tyler
    Ibarra, Claudia
    Barken, Derren
    Dervieux, Thierry
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S846 - S847
  • [36] Erythrocyte complement receptor 1 (ECR1) and erythrocyte-bound C4d (EC4d) in the prediction of poor pregnancy outcomes in systemic lupus erythematosus (SLE)
    Conklin, John
    Golpanian, Michael
    Engel, Alexis
    Izmirly, Peter
    Belmont, H. Michael
    Dervieux, Thierry
    Buyon, Jill P.
    Alexander, Roberta Vezza
    LUPUS SCIENCE & MEDICINE, 2022, 9 (01):
  • [37] An Economic Evaluation on the Impact of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using Complement C4d Activation Products in a Multivariate Assay Panel (MAP)
    Clarke, Ann E.
    Goss, Tom
    Piscitello, Andrew
    Chandra, Tarun
    O'Malley, Tyler
    Dervieux, Thierry
    Powell, Tami
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [38] Erythrocyte Complement Receptor 1 (ECR1) and Erythrocyte Bound C4d (EC4d) Associate with Adverse Pregnancy Outcomes and Preeclampsia in Pregnant Women with Systemic Lupus Erythematosus (SLE)
    Buyon, Jill
    Conklin, John
    Golpanian, Michael
    Ligayon, JoAnne
    Dervieux, Thierry
    Izmirly, Peter
    Belmont, H. Michael
    Salmon, Jane
    Alexander, Roberta Vezza
    ARTHRITIS & RHEUMATOLOGY, 2020, 72